NCT05247125View on ClinicalTrials.gov

The Role of Circadian Factors in Regulation of Neuroplasticity in Ischemic Stroke (Interventional)

PHASE4RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

January 30, 2026

Study Completion Date

December 31, 2026

Conditions
Ischemic Stroke, AcuteSleep Disorders, Circadian Rhythm
Interventions
COMBINATION_PRODUCT

Blue light exposure + Melatonin treatment

3 mg Melatonin pill will be given 1 hour before going to bed. Blue light exposure will be performed during 30-minute sessions with the use of the lamps (Lumie/Vitamin L) in the morning.

DRUG

Melatonin treatment

3 mg Melatonin pill will be given 1 hour before going to bed.

DEVICE

Blue light exposure

Blue light exposure will be performed during 30-minute sessions with the use of the lamps (Lumie/Vitamin L) in the morning.

COMBINATION_PRODUCT

Placebo

Placebo light exposure will be performed by using lamp turned off; and placebo pill will be given in the evening

Trial Locations (1)

197341

RECRUITING

Almazov National Medical Research Centre, Saint Petersburg

All Listed Sponsors
lead

Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health

OTHER